



GlyTherix® Ltd

Company profile

GlyTherix is an Australian Immuno-Oncology Company with unique assets in the treatment of solid tumors with high unmet need. GlyTherix has:

- The ability to address a clear market need for new therapies to target solid tumors
- A clear development pathway
- A clear understanding of the requirements for the pipeline development programs
- The leadership team needed to manage the planned research programs
- A clear end goal which is to maximize the return on its intellectual property assets

Pipeline and Developments

Miltuximab® (our patented antibody) targets Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.

We have completed a first in human trial using Miltuximab® to evaluate the safety and tumor targeting of Miltuximab® in patients with advanced prostate, bladder and pancreatic cancer. A total of 12 patients were dosed with no drug-related adverse reactions whatsoever.

Miltuximab® is a first in class product. No-one else presently has an anti-glypican-1 therapy, in clinical development, for these cancers. For any antibody-based therapy one should not only be the first but also the best in class. We have a very strong patent estate around both target and antibody.

To achieve this GlyTherix is developing pipeline with:

- The best version of the antibody; which is most effective and safe as well as acceptable to our future licensee partners
- A Phase 1 clinical trial using ¹⁷⁷Lu-Miltuximab®

What We are Looking For

GlyTherix is raising US\$20M capital to fund the commercialization of Miltuximab®, that targets cancers that have a major underserved need, in a high value market, with the protection of a growing intellectual property position (4 families) and a reduced commercial risk profile.

Contact

Name: Brad Walsh
Position: CEO
Company: GlyTherix Ltd
Address: Ground Floor, 75 Talavera Road, Macquarie Park NSW 2113
Website: glytherix.com
Phone: +61 413 231 296
Email: brad.walsh@glytherix.com



Speaker Profile

Dr Brad Walsh, Chief Executive Officer, GlyTherix Ltd


Dr Brad Walsh is Chief Executive Officer and a Director of Minomic International Ltd, a Sydney-based biotechnology company specialising in immuno-oncology.

He founded Minomic to bring to market an innovative biomarker for prostate cancer.

Dr Walsh has led Minomic's scientific and business development, raising A\$26 million and bringing the company to a point at which its first major product, MiCheck®, has progressed through a series of clinical trials in preparation for release to the US market.

A pipeline of potential new therapeutics is in development for prostate, bladder and pancreatic cancer and this has prompted the spin out of a new company, GlyTherix Ltd.

Dr Walsh's career in biotechnology began with a PhD in protein chemistry. Over the following years he led research groups in government agencies, universities and hospitals and was a key part of the establishment of a major national research facility, before forming Minomic in 2007.



He continues to be active in research collaborations and academic supervision and was a joint recipient of one of Australia's most prestigious science awards, a Eureka Prize, for Interdisciplinary Research in 2015. He has co-authored 90 peer reviewed papers and book chapters and six patents.